Unlocking the Potential of ACSM6 as a Drug Target and Biomarker

Target Name: ACSM6

NCBI ID: G142827

ACSM6

Unlocking the Potential of ACSM6 as a Drug Target and Biomarker

The ACSM6 enzyme, also known as acyl-coenzyme A synthetase ACSM6, is a critical protein involved in the synthesis of the key precursor molecule for the tricarboxylic acid (TCA) cycle in mitochondria. The TCA cycle is a central metabolic pathway that generates energy, primarily in the form of ATP, and is crucial for the survival of eukaryotic cells. ACSM6, as a key enzyme in the TCA cycle, plays a vital role in maintaining cellular energy homeostasis.

Recent studies have identified ACSM6 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will explore the current understanding of ACSM6 and its potential as a drug target and biomarker, with a focus on its role in the context of these diseases.

Understanding ACSM6: Structure and Function

The ACSM6 enzyme is a member of the superfamily of Coenzyme A synthetases, which are involved in the synthesis of the essential coenzyme A molecule from various precursors. The ACSM6 enzyme catalyzes the conversion of two acetyl-CoA molecules to acyl-CoA synthetase intermediates, which are then converted to the final product, 2-acetyl-CoA.

The ACSM6 enzyme has a unique structure that consists of a catalytic core and a transmembrane region. The catalytic core is composed of multiple domains, including an N-terminal alpha-helices, a catalytic center, and a C-terminal domain that includes a putative active site for substrate recognition. The transmembrane region is responsible for the maintenance of the enzyme's structural integrity and localization to the membrane.

The function of ACSM6 is highly regulated by various factors, including genetic and environmental factors. Multiple studies have demonstrated that ACSM6 is involved in a wide range of cellular processes, including metabolism, stress response, and cell signaling.

Potential Drug Targets

The potential of ACSM6 as a drug target is based on its involvement in various cellular processes that are associated with the development and progression of various diseases. Here are some of the potential drug targets for ACSM6:

1. Cancer:

In many cancers, the ACSM6 enzyme is over-expressed or mutated, leading to disruptions in the TCA cycle and increased energy production. This increased energy production can contribute to the growth and survival of cancer cells. Targeting ACSM6 with small molecules or inhibitors has been shown to be an effective strategy for cancer treatment.

1. Neurodegenerative Diseases:

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. The ACSM6 enzyme has been implicated in the development and progression of these diseases due to its role in the production of the neurotransmitter acetylcholine, which is involved in the regulation of neural communication.

1. Metabolic Disorders:

Metabolic disorders, such as obesity and type 2 diabetes, are characterized by disruptions in energy metabolism and obesity. The ACSM6 enzyme is involved in the TCA cycle, which is responsible for the production of the key substrates for the ketone bodies, which are involved in energy metabolism. Therefore, targeting

Protein Name: Acyl-CoA Synthetase Medium Chain Family Member 6

Functions: Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism

The "ACSM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACSM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets